VcMMAE Size:Solid 10 mg Smiles: O[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)CO

Smiles: O[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)CO

Smiles: CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@@]21C

which is only slightly less potent than in bovine serum

Formula: C10H11F3N2O5

IC87114 (5 µM) potently inhibits N-formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated phosphatidylinositol triphosphate (PIP3) biosynthesis and chemotaxis

VcMMAE Size:Solid 10 mg Smiles: O[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)COVcMMAE is a MMAE derivative with valine citrulline (Vc) linker. VcMMAE can be used to make antibody drug conjugate. VcMMAE is a anti mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine citrulline (vc). Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to